The University of Chicago

University of California

Michigan State University

Janssen Pharmaceuticals, Inc.

Olaf Schneewind

Dominique Missiakas

Hwan Keun Kim

Alice G Cheng

Carla Emolo

Andrea Dedent

Molly McAdow

Sarkis K Mazmanian

Gwen Liu

Juliane Bubeck-Wardenburg

Hung Ton-That

Dominique M Missiakas

Jeroen Geurtsen

Robert R Brubaker

R William DePaolo

Katie A Overheim

Lena Thomer

Elizabeth M Morrin

Bana Jabri

Hye-Young Kim

Hong Ton-That

Brook Ragle

Mark De Been

Monica Burts

Deborah M Anderson

Kristin L DeBord

Vilasack Thammavongsa

Justin Kern

The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by abacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.

Compositions and methods related to protein A (SpA) variants

Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing Hla to provide immunoprotection againstpneumonia. In certain aspects the invention includes a Hla with reduced toxicity, represented by a recombinant mutant form of Hla (HlaH35L) in which histidine 35 is converted to leucine, which can be used to abrogate the productive assembly of the toxin and protect a subject from staphylococcal pneumonia.

Methods and compositions related to immunizing againstlung diseases and conditions

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by abacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa). Further aspects relate to immunogenic compositions comprising at least one Staphylococcal coagulase R Domain, wherein the R Domain is 80% identical in sequence to a R Domain.

Compositions and methods related to antibodies that neutralize coagulase activity duringdisease

The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by abacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve coagulase Domains 1-2 and variants thereof.

Staphylococcal coagulase antigens and methods of their use

Compositions and methods related to Protein A (SpA) Variants

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by abacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).

Compositions and methods related to antibodies to Staphylococcal protein A

The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve coagulase Domains 1-2 and variants thereof.

The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by abacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant or an antibody directed thereto.

Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by abacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria, in certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa).

[object Object]

Disclosed are methods and compositions for treating or preventing abacterial infection using a non-toxigenic Protein A (SpA) variant.

Compositions and methods related to antibodies to staphylococcal protein A

Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing HIa to provide immunoprotection againstpneumonia. In certain aspects the invention includes a HIa with reduced toxicity, represented by a recombinant mutant form of HIa (HlaH35L) in which histidine 35 is convened to leucine, which can be used to abrogate the productive assembly of the toxin and protect a subject from staphylococcal pneumonia.

Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions

Growing community of inventors

Chicago, IL, United States of America

Olaf Schneewind